Lundbeck’s €905 Million Acquisition of Prexton Therapeutics

Dechert LLP advised biopharmaceutical company Prexton Therapeutics B.V. (Prexton) and its selling shareholders, including M Ventures, in the deal. H. Lundbeck A/S and Prexton Therapeutics BV…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

This content is for Standard 1 Year members only.
Login Join Now